Skip to content
Accelsiors
  • Home
      • Project Management
      • Central and Risk-based Monitoring
      • Regulatory Solutions
      • Monitoring and Site Management
      • Data Management
      • Drug Safety Management and Pharmacovigilance
      • Record Management
      • Quality Assurance
      • Biostatistics and Statistical Programming
      • Medical Writing
      • Pharmacology, Clinical Pharmacology, Modelling & Simulation
      • Real World Data and Real World Evidence
    • Early Phase Services
      • Regulatory Consultancy
      • Medical and Pharmacovigilance Support
      • Legal, GDPR and Representation Services
      • Drug Development Consultancy
      • Endocrinology
      • Autoimmune Disorders
      • Infectious Diseases
      • Respiratory
      • Hepatology and Gastrointestinal
      • Nervous System
      • Nephrology
      • Women’s Health
      • Oncology
    • Biosimilars
    • Generics
    • Pediatric Studies
    • Cell and Gene Therapy
    • Vaccines
    • Microbiome
    • Orphan Disorders
    • Quality Drive™
    • StrongCORE Scientific™
    • AcceleROUTE™
    • WideSCOPE Intelligence™
    • ProPATIENT Solutions™
    • AcceShield™
    • Our company
    • Leadership
    • Global Reach
    • News
    • White Papers
    • Student Hub
  • Contact
Search
Schedule a Meeting
Close

News & Latest Announcements

Published October 20, 2025

The Patient Who Can’t Wait: Why Personalized Support is Key in Cross-Border Trials

Imagine a patient in Lisbon diagnosed with a rare form of melanoma. Their local treatment options have been exhausted. Their physician discovers a promising Phase I…

Read article
Published October 15, 2025

Europe’s Clinical Trial Ecosystem: A Ticking Clock for Biotech Innovators?

The European Union presents a frustrating paradox. It is a global powerhouse of scientific intellect, advanced healthcare, and pharmaceutical investment, yet it is steadily losing its…

Read article
Published October 14, 2025

Mitigating Risks: How CROs Ensure Safe CAR-T cells Trials

CAR T therapy has immense potential in autoimmune diseases like multiple sclerosis, but safety remains the central concern that guides every decision. The objective is to…

Read article
Published October 8, 2025

Are You Ready to Lead the Patient-Centric Revolution?

The clinical research industry stands at an inflection point, facing a choice between two distinct futures.  The first path is “friendliness.” It’s the continuation of the…

Read article
Published October 7, 2025

Inside the Trials: Early Evidence of CAR-T cell therapy in Progressive MS

The idea of using CAR-T cell therapy for multiple sclerosis has moved from speculation to practical testing in the clinic. Early reports show that this therapeutic…

Read article
Published October 1, 2025

Metrics That Matter: Measuring Patient Experience in Trials

In business, the adage is simple: what gets measured gets managed. We apply this rigor to our financial performance and operational efficiency, so why not to…

Read article
Published September 29, 2025

CAR-T cells vs. Anti-CD20 antibodies: Breaking Through the CNS Barrier in MS

Anti-CD20 monoclonal antibodies like ocrelizumab have advanced MS treatment significantly and offered real hope to many patients. Yet, over time, their limitations have become harder to…

Read article
Published September 24, 2025

Co-Created Protocols: Co-Writing the Protocol with Patients

For decades, the clinical trial industry has asked patients for their data, their time, and their bodies. It’s time we started asking for their expertise.  True…

Read article
Published September 23, 2025

Why CAR-T Cell Therapy is Redefining Autoimmune Treatment

For decades, patients with multiple sclerosis (MS) and other autoimmune diseases have relied on therapies that manage symptoms but rarely alter the long-term trajectory of disease.…

Read article
  • Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next
Accelsiors

Accelerating life-changing therapies through rigorous clinical research and Hexa-Helix™ innovation.

Company

  • Hexa-Helix™
  • About
  • News
  • Global Reach
  • Contact

FOLLOW US

  • LinkedIn
  • Facebook

pRIVACY pOLICY
& tERMS OF USE


© 2026 Accelsiors. Designed & Powered by Accelsiors. All rights reserved.

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}